Data From Phase 3 Trials Demonstrate Efficacy of Dupilumab for Treating COPD, Type 2 Inflammation

Patients with uncontrolled chronic obstructive pulmonary disease (COPD) and type 2 inflammation had significantly better lung function at least a year into a dupilumab regimen.

Related Keywords

Ivelin Radkov ,Naimish Patel ,Georged Yancopoulos ,European Medicines Agency ,Global Development ,Copd ,Phase 3 Trials ,Dupilumab ,Type 2 Inflammation ,